Summary
This document was drafted on the basis of the Transparency Committee opinion, French National Authority for Health, dated 27 February 2019.
It found insufficient clinical benefit of ESMYA* for the treatment of uterine fibroids to justify reimbursement. They conclude:
- The actual clinical benefit of ESMYA is insufficient to justify its reimbursement by public funding in its two indications.
- Not approved for non-hospital pharmacy reimbursement or for hospital treatment.
*ESMYA - (ulipristal acetate), progesterone receptor modulator.
ESMYA: Insufficient clinical benefit to justify reimbursement for the treatment of uterine fibroids (February 2019)
https://www.has-sante.fr/upload/docs/application/pdf/2019-09/esmya_summary_ct17283.pdf
0
reactions so far
0 Comments
Recommended Comments
There are no comments to display.
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now